Mumbai: The stock market witnessed significant volatility on Thursday. While the Sensex and Nifty showed a strong surge at the opening of trading, the initial momentum slowed lanugo by the time the market closed. However, both indices sealed in the untried zone without three subsequent days of decline. Meanwhile, one visitor from the Bajaj Group created a stir throughout the day, hitting a 20% upper circuit.
Why are investors rejoicing?
Investors who had invested in Bajaj Consumer Care Limited, a visitor of the Bajaj Group, had a unconfined day on Thursday. The stock saw such strong ownership that it hit a 20% upper spin on the BSE. Bajaj Consumer Care shares opened at Rs 270, a sharp jump from its previous day's latter price of Rs 248.25, and then quickly hit the upper circuit, latter at Rs 296.90.
This sudden and rapid surge in the share price moreover impacted the company's market capitalization. The company's market cap jumped to Rs 3860 crore. It's worth noting that Thursday's latter price is tropical to the stock's 52-week upper of Rs 310. The 52-week low is Rs 151.
Why the phenomenal surge in this share?
The reasons overdue the sudden surge in this Bajaj Group share are the spanking-new December quarter results released by the company. The FMCG visitor reported in its results for the quarter ended December 31, 2025, that its Profit Without Tax (PAT) increased by 83.2% to 46.37 crore, compared to 25.31 crore in the same quarter of the previous year.
Bajaj Consumer Care stated that its volume market share is currently at its lifetime upper level in the last eight quarters. Looking at the quarterly results, EBITDA registered a 109.5% increase in the December quarter, rising to 56.9 crore from 27.2 crore in the third quarter of the previous year.
How did the company's earnings increase?
In a statement released without the quarterly results, Bajaj Consumer Care said that its domestic merchantry growth was driven by double-digit growth in sales of its flagship product, Bajaj Almond Drops Hair Oil (ADHO). Sales growth for products in the Non-ADHO portfolio remained in single digits.
